Background and Objective: In health technology assessment, the evidence
obtained from clinical trials regarding multiple clinical outcomes is used to
support reimbursement claims. At present, the relevance of these outcome
measures for patients is, however, not systematically assessed, and judgments
on their relevance may differ among patients and healthcare professionals.
The analytic hierarchy process (AHP) is a technique for multi-criteria decision
analysis that can be used for preference elicitation. In the present study,
we explored the value of using the AHP to prioritize the relevance of outcome
measures for major depression by patients, psychiatrists and psychotherapists,
and to elicit preferences for alternative healthcare interventions regarding this
weighted set of outcome measures.
Methods: Supported by the pairwise comparison technique of the AHP, a patient
group and an expert group of psychiatrists and psychotherapists discussed and
estimated the priorities of the clinical outcome measures of antidepressant
treatment. These outcome measures included remission of depression, response
to drug treatment, no relapse, (serious) adverse events, social function, no anxiety,
no pain, and cognitive function. Clinical evidence on the outcomes of three
antidepressants regarding these outcome measures was derived from a previous
benefit assessment by the Institute for Quality and Efficiency in Health Care
(IQWiG; Institut fu¨r Qualita¨ t und Wirtschaftlichkeit im Gesundheitswesen).
Results: The most important outcome measures according to the patients
were, in order of decreasing importance: response to drug treatment, cognitive
function, social function, no anxiety, remission, and no relapse. The patients and
the experts showed some remarkable differences regarding the relative importance
of response (weight patients = 0.37; weight experts = 0.05) and remission (weight
patients = 0.09; weight experts = 0.40); however, both experts and patients
agreed upon the list of the six most important measures, with experts only
adding one additional outcome measure.
Conclusions: The AHP can easily be used to elicit patient preferences and the
study has demonstrated differences between patients and experts. The AHP is
useful for policy makers in combining multiple clinical outcomes of healthcare
interventions grounded in randomized controlled trials in an overall
health economic evaluation. This may be particularly relevant in cases where
different outcome measures lead to conflicting results about the best alternative
to reimburse. Alternatively, AHP may also support researchers in selecting
(primary) outcome measures with the highest relevance